QT prolongation can be attributable to various causes that can be categorised as acquired or congenital. Arrhythmias related to QT prolongation can result in clinical presentations, such as syncope and sudden cardiac death. The perioperative period presents a number of issues that may affect a patient's risk of developing polymorphic ventricular tachycardia or torsades de pointes. Although most patients may have an unremarkable perioperative course, some may have complications; this review article aims to help clinicians avoid potential complications, and to help them address treatment for perioperative issues that may occur.
males and >460 ms in females. 1 However, the 99th percentile values are !460 ms (prepuberty), !470 ms (males), and !480 ms (females); these values are probably the most useful and actionable. With increasingly longer QTc values, the pretest probability of a patient having an LQTS-causing mutation also increases. In fact, genetic testing for LQTS is a Class I indication for asymptomatic, post-pubertal individuals if an otherwise idiopathic QTc of !500 ms (!480 ms prepuberty) is detected and persists on serial ECGs. 2 In addition, increasingly
prolonged QTc values portend a higher risk of potentially lethal arrhythmic events. 3, 4 Of note, the QT interval on an ECG can vary in an individual, depending on autonomic state, circadian rhythm, medication effect, or electrolyte imbalance.
5
The American Heart Association and American College of Cardiology have recommended standardised methods 1 of measuring the QT interval. Any computer-generated measurement should be confirmed manually. To confirm the QTc, Leads II and V5 optimally are used. 6 The preferred QT measurement method draws a tangent line along the maximum slope of the descending limb of the T wave; the end of the QT interval is the point at which the tangent line intersects the isoelectric line defined by the TP segment ( Fig. 1 ). Care should be taken to exclude the U wave, when present, unless it exceeds half of the T-wave amplitude. 7 Care should also be taken to avoid inadvertent inclusion of the P wave at higher heart rates. When either atrial fibrillation or sinus arrhythmia is present, all of the QT intervals and the preceding RR intervals in the QRS complexes should be averaged to minimise overestimation of the QTc. Specifically, simply taking the longest QT interval and dividing by the square root of the shortest RR interval will result in a gross overestimation of the true QTc. 8 The formula classically used to correct for heart rate is the Bazett formula. 9 However, this formula may overestimate the true QTc at faster heart rates, and conversely, it may underestimate the true QTc at slower heart rates. 1, 10 Corrected QT ¼ QT/√RR
Congenital LQTS vs acquired QT prolongation
Congenital LQTS is a potentially inherited cardiac channelopathy that manifests with a prolonged QT interval and polymorphic ventricular tachycardia, characterised by TdP, with an estimated prevalence rate of one in 2500. 2, 11 To date, 17 LQTS-susceptibility genes have been identified (Table 1) , and among patients with a high index of suspicion for LQTS, the LQTS genetic test will be positive for about 75e80%. Almost all the genotype positivity is confined to three canonical LQTS- QT prolongation and subsequent TdP (Fig. 2) caused by medications, electrolyte disturbances, or disease was previously termed acquired LQTS. However, acquired QT prolongation is the preferred expression. Although most cases of acquired QT prolongation are not genetically based, the first manifestation of congenital LQTS may occur in the setting of acquired QT prolongation. For example, approximately 5e10% of patients with drug-induced QT prolongation may have an underlying LQTS-causative mutation. 29 Before pursuing a diagnosis of congenital LQTS, reversible causes of QT prolongation must be excluded. Possible causes may include medication, myocardial ischaemia, hypothermia, and electrolyte abnormalities (e.g. hypokalaemia, hypomagnesaemia, or hypocalcaemia).
Genetics of congenital LQTS
In congenital LQTS, at least 17 types with associated gene mutations have been identified (Table 1) . Among the described phenotypes of congenital LQTS is Jervell and Lange-Nielsen syndrome, an autosomal recessive trait often resulting in severe LQTS and concomitant sensorineural hearing loss. 30 Another is RomanoeWard syndrome, a more common autosomal-dominant condition not associated with hearing impairment.
31,32
The aforementioned canonical LQTS-susceptibility genes encode the critical pore-forming a subunits of cardiac ion channels, and most are inherited in an autosomal-dominant pattern. 2, 12 Other mutations involve proteins interacting with the ion channels; many mutations identified in these components have unknown effects and are thus termed variants of unknown significance.
33

Clinical features of congenital LQTS
The phenotypic presentation of LQTS can be variable. Patients may be asymptomatic, with evidence of LQTS only on a 12-lead ECG at rest or with repolarisation stress (e.g. sympathetic stimulation during exercise testing) or other forms of testing (e.g. epinephrine stress testing). 34 The presentation of congenital LQTS can be symptomatic, ranging from palpitations to an event, such as SCD. The index event for patients with a known disease-causing mutation varies by age and sex. Male patients most commonly present with an LQTS event before age 18 yrs, whereas female patients are more likely to present with an event after puberty. The history must be obtained carefully from patients who present with syncope to exclude neurocardiogenic syncope and orthostatic intolerancedthese are not considered relevant LQTS-attributable events. The history should also focus on identifying possible triggers of LQTS events. A number of triggers have been identified that are typically associated with LQT1, LQT2, and LQT3, the most common genotypes.
14 Exercise is a trigger most commonly associated with LQT1. A heightened adrenergic state results in prolongation of the QTc; thus, exercise testing is used to provoke ECG manifestation in individuals with suspected LQT1. 14 In patients with LQT2, situations of acute emotion or startling (e.g. from an alarm clock) can provoke an event. Additionally, pause-dependent events with TdP, similar to those seen in patients with drug-induced QT prolongation, are typical of The diagnostic evaluation of congenital LQTS can be facilitated by calculating the Schwartz risk score, also termed the LQTS score. This weighted scoring system suggests a high probability of LQTS if the score is >3.5 and a low probability if the score is <1. atrioventricular nodal block, which was 2:1 atrioventricular block in the majority of patients and complete atrioventricular block in only two patients. A prospective cohort study of LQTS probands also reported an increased risk of bradycardia compared with family members, 45 although the majority (80%)
Sudden death in congenital LQTS
were receiving b-blocker therapy at the time of enrolment.
Blunted heart-rate response to exercise
Congenital LQTS is also associated with mild chronotropic incompetence. Patients with congenital LQTS (LQT1 and LQT2), even if not receiving b-blocker therapy, can have a blunted heart-rate response upon standing from a supine position. In one study, the heart rate for patients with congenital LQTS increased by a mean [standard deviation (SD)] of 10.5 (15.5) beats min À1 , whereas controls had an increase of 18.8 (15.3) beats min À1 .
46
Sinus node dysfunction is particularly prominent in LQT1, and exercise testing of a cohort of patients with LQT1 showed significantly lower maximal heart rates compared with either healthy controls or patients with LQT2. 47 This difference may be explained by findings from in vitro studies that reported a substantive contribution of I Ks to sinus node activity.
48
Torsades de pointes
Patients with congenital LQTS are at risk of TdP (Fig. 2) , a polymorphic ventricular tachycardia characterised by 'twisting' of the QRS axis around the isoelectric line. 49 Besides sex, age, genotype, and QTc, other predictors of TdP risk include short-term variability in QTc duration, the interval between the peak of the T wave and its end, and the electromechanical window.
49,50
The electrophysiological mechanisms underlying TdP are complex, and a conceptual framework for understanding the pathogenesis of TdP (termed TRIaD) has been proposed. 49, 51 In the setting of certain key features, a common trigger for TdP is early afterdepolarisation. 49 The key features of this framework are as follows: 1) Triangulation: the action potential shape becomes more triangular, with loss of the plateau typically seen in Phase 2 depolarisation and slowing of Phase 3 repolarisation. 2) Reverse use dependence: the action potential duration is prolonged when depolarisation occurs after a pause. 3) Instability: short-term variability in action potential duration, characteristically a 'shortelongeshort' pattern preceding TdP. 4) Dispersion: the action potential duration becomes more heterogeneous across the myocardial wall.
Genetic testing is a reasonable consideration in patients with isolated drug-induced QT prolongation or TdP, but testing should be addressed on an individualised basis. As discussed previously, up to 10e15% of these patients have coding region variants in LQTS genes. 52 The current recommendation from the Heart Rhythm Society/European Heart Rhythm Association is to perform a 12-lead ECG on first-degree relatives and to consider genetic testing. 36,53e55 b-Blockers significantly reduce the rate of cardiac events (SCD, ACA, and syncope) in patients with LQT1, LQT2, and LQT3, but they are most efficacious in LQT1.
56 Not all bblockers are of equal efficacy, however, and treatment with nadolol is preferable to metoprolol. 57 Propranolol has also been shown to be effective in patients with congenital LQTS, showing greater QTc shortening than either metoprolol or nadolol.
57
The efficacy of certain treatments can be genotype specific.
14,53 Patients with LQT1 are particularly sensitive to catecholamine-provoked events, and hence, respond very well to anti-adrenergic therapy.
14,55 In fact, 'failures' of b-blocker therapy in patients with LQT1 arise primarily from noncompliance and the use of QT-prolonging drugs. 55 In contrast, patients with LQT2 and LQT3 have a higher incidence of cardiac events, despite b-blockade.
14,53
Patients with LQT3 have mutations in SCN5A that confer a gain of function; thus, sodium channel blockers, typically mexiletine, have been tried as adjunctive therapies in this cohort. This medication effectively attenuates the QTc in patients with LQT3 and decreases the frequency of LQT3-triggered events. 58, 59 However, the response to mexiletine appears to have mutation-specific characteristics in LQT3; one report described a paradoxically worsened clinical phenotype in a patient having an SCN5A mutation with Brugada-like features from its effect on the sodium current.
60
Non-pharmacological therapies 
Acquired QT prolongation
The QT interval can prolong with genetic and non-genetic perturbations of repolarisation reserve. Any factor that causes a net reduction in the outward current will prolong repolarisation and, therefore, lengthen the QT interval. This net reduction can be from increased inward sodium or calcium current, or from decreased outward potassium current.
23,70,71
A range of medications can prolong the QT interval ( Table 2) . As mentioned previously, most of these agents inhibit the rapid component of the delayed rectifier outward potassium current, I Kr , which is responsible for Phase 3 repolarisation of the cardiac action potential. 76 Of note, I Kr is encoded by KCNH2, the same gene implicated in LQT2 (Table 1) . Drug classes that are most commonly implicated include anti-arrhythmics (Classes IA and III), antipsychotics, promotility agents, and certain antimicrobials. 72 Interestingly, although amiodarone blocks I Kr and prolongs the QT interval, it is uncommonly associated with TdP. 77 The low proarrhythmogenicity of amiodarone is likely attributable to its complex multiclass anti-arrhythmic effects, resulting in more homogeneous prolongation of ventricular repolarisation throughout the myocardial cell layers.
78
In addition, many of the known causative drugs (e.g. Class III anti-arrhythmics) show reverse use dependence, a phenomenon whereby the drug has a more pronounced effect on blocking the hERG channel at slower heart rates. Therefore, the drug is more likely to cause QT prolongation in the setting of bradycardia.
72,79 Bradycardia itself increases the risk of polymorphic ventricular tachycardia in acquired QT prolongation by decreasing the extracellular concentration of potassium. 80 Newer Class III anti-arrhythmics are powerful inhibitors of the I Kr current and are associated with high rates of TdP (1e4%).
81e83
The torsadogenic potential of a drug is associated with the QTc value and the transmural dispersion of repolarisation. Transmural dispersion of repolarisation is defined as the time between the peak and the end of the T wave in a precordial lead, and it is caused by differences in the duration of action potentials among the various populations of cells throughout the myocardium. 84 Drugs that increase both QTc and transmural dispersion of repolarisation are highly torsadogenic, whereas drugs that only prolong the QTc rarely induce TdP. 85 Drug-induced prolongation of the QTc typically occurs through concentration-dependent blocking of cardiac hERG or Kv11.1 potassium channels, as mentioned previously. 86 ,87 An updated list of drugs, with known and potential risks to cause QT prolongation and potentially TdP, can be found online.
88
Common non-pharmacological factors implicated in acquired QT prolongation or TdP include electrolyte disturbances (hypokalaemia, hypomagnesaemia, and hypocalcaemia) and patient sex.
80,89e91 Females have a markedly increased risk of acquired QT prolongation or TdP because of the modulating effects of gonadal steroids on ion channel function. 92, 93 Cardiac factors, such as ischaemic or structural heart disease, may also contribute to QT prolongation, but concomitant diuretic therapy with resultant electrolyte abnormalities may also be a cause. 94, 95 Intracranial events, such as subarachnoid haemorrhage, stroke, and brain surgery, are also strongly associated with acquired QT prolongation. The cause is probably hypokalaemia associated with a catecholamine surge or possible autonomic dysregulation. Certain genomic polymorphisms or clinically silent mutations may predispose the development of QT prolongation and subsequent TdP in the setting of other provocations. As such, a proportion of patients with seemingly acquired QT prolongation or TdP may in fact have congenital LQTS.
22,23,99,100 In a study of 92 patients with a history of drug-induced LQTS, 10e15% had coding region variants in the major known LQTS genes, and five patients had mutations consistent with congenital LQT1, LQT2, or LQT3.
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Management of patients with acquired QT prolongation or TdP
The management of patients with acquired QT prolongation, with or without TdP, relies on subsequent avoidance of known triggers, such as medications and non-pharmacological factors, as described previously. 101 Any drug-precipitated event should be reversed, if possible. Electrolyte abnormalities should be corrected, particularly hypokalaemia. For patients with a QTc >500 ms, inpatient management should be considered to correct the underlying issue. For patients with TdP, acute therapy should follow advanced cardiovascular life-support guidelines, with nonsynchronised electrical cardioversion. 102 Magnesium sulphate (2 g) should also be administered intravenously to shorten the QT interval and potentially stabilise the cardiac Patients with bradycardia or pause-dependent TdP may benefit from temporary or even permanent pacemaker implantation. 104 The overdrive pacing should shorten the QT interval, decrease its dispersion of refractoriness, and, as a result, decrease the frequency of early afterdepolarisationtype premature ventricular complexes. 105 Typically, overdrive pacing starts at 90 beats min À1 . Isoproterenol infusion can also be considered to increase the heart rate, imparting similar effects as overdrive pacing.
64
Anaesthesia implications for LQTS
Because of the abnormal cardiac repolarisation of patients with LQTS and the risk of significant morbidity and mortality in the perioperative period, anaesthesiologists should be aware of preventive and treatment options for this cohort. Approximately 40 fatal cases of perioperative TdP have been reported in the literature in the past 30 yrs; however, because TdP is often self-limited, it is likely to be under-reported. No consensus guidelines exist that outline the anaesthetic management of patients with LQTS. Only limited articles, mostly case reports and case series, describe management of these patients. In addition, the QT-prolonging effects of medications have been studied mostly in healthy individuals. Although the perioperative risk of TdP and SCD is low even among patients with congenital LQTS, 112 precautions need to be taken. One goal of perioperative care is to minimise the risk of potential malignant ventricular arrhythmias. The preferred medications and those to avoid in the perioperative period are summarised in Table 3 .
Preoperative management
Preoperative evaluation is the cornerstone of perioperative management. A full preoperative history and physical examination, including an ECG, should be obtained in any patient with a history of congenital LQTS, acquired QT prolongation, or TdP. Electrophysiology consultation should be considered. Arrhythmia-attributable symptoms, such as syncope or ACA, should be investigated. 84 The medication list should be screened for drugs that are implicated in QT prolongation (Table 2) . Certainly, the preference is to hold or avoid exposure to any QT-prolonging medications whenever possible. Patients receiving b-blockers should continue their b-blockers through the procedure. 113 If the patient has not been treated with a b-blocker, it should not necessarily be started perioperatively because some forms of LQTS (e.g. LQT3) may have QT prolongation with bradycardia. If an ECG obtained for other preoperative risk factors also shows a prolonged QTc (>99th percentile, as noted previously), the patient should be carefully evaluated and further history or laboratory tests may need to be obtained. Symptoms of LQTS may include syncope, deafness, or an unexplained family history of SCD. Importantly, a patient with QTc !500 ms must have the cause of the prolonged QT interval definitively established.
113,114
Laboratory tests, specifically serum electrolytes, should be checked and levels optimised. Hypokalaemia, hypomagnesaemia, and hypocalcaemia are associated with delayed myocardial repolarisation and, therefore, QT prolongation. 112 Any necessary replacements should be undertaken before surgery. 115 As a rule of thumb, the potassium should be >4.5 mmol litre
À1
and the magnesium should be >2.0 mg dl À1 .
116,117
Intraoperative management
General conditions and sedation
Much of the difficulty in managing patients with LQTS is because the LQTS is unrecognised in this cohort. Asymptomatic patients with normal QTc may still have TdP develop during the perioperative period, thereby unmasking latent LQTS. 118 A quiet operating-room environment is needed before inducing anaesthesia because certain subtypes of congenital LQTS may be triggered by auditory stimuli.
14, 112, 119 Pain and anxiety may trigger arrhythmias in patients with LQTS. As such, premedication (preceding entry to the operating room) is advised. Midazolam, a common sedative, is safe because it neither prolongs the QTc nor affects electrical dispersion across the myocardium. 115,120 Dexmedetomidine, however, increases the QTc in children. 121 Hypothermia, which can prolong the QT interval, should be avoided by warming the patient in each operative period (before operation, intraoperatively, and after operation) to maintain a temperature of 37 C. 112, 122, 123 Hypoxia and hypercarbia should also be avoided because of their effect in increasing sympathetic tone. 118 Necessary precautions should be taken for patients with a pacemaker or an ICD. For patients with a device and LQT3, cardiac pacing may be useful to prevent bradycardia, which can prolong the QT interval. 113, 114, 124 A non-tracking or nonsensing mode (VOO or DOO) can be programmed if patients require pacing; these modes prevent the device from detecting external electromagnetic interference (e.g. from electrocautery). If an ICD is present, tachyarrhythmia therapy should be programmed off and defibrillation pads must be placed as a precautionary measure before induction. The QT interval should be monitored throughout the procedure.
Induction of general anaesthesia
A study of 469 patients from the Vitamins in Nitrous Oxide trial undergoing non-cardiac surgery showed that 80% of patients had a significant lengthening of the QTc [mean (SD)
DQTc, 23 ms
26
; 95% confidence interval, 20e25 ms; P<0.001) with the cumulative effect of drugs administered during general anaesthesia. 125 Induction and intubation are precarious procedures because the haemodynamic response may lead to arrhythmogenic activity. Tracheal intubation itself may prolong the QT interval by activating the sympathetic nervous system, and the medications given for induction may further increase the QTc.
126,127
Analgesia
Optimal pain management will also help prevent arrhythmogenic activity. Lidocaine (1.5 mg kg
À1
), administered intravenously during induction, may prevent QTc prolongation during intubation, although this drug is usually reserved for patients with high-risk LQTS. 128 Fentanyl (2 mg kg À1 ) to blunt the haemodynamic response is also useful and safe in patients with LQTS. 129, 130 In addition, alfentanil, remifentanil, and morphine have been used safely in patients with LQTS; however, methadone and sufentanil prolong the QTc. 
Intravenous agents
The effect of propofol on the QTc is controversial, although the drug is known to not accentuate transmural dispersion of repolarisation.
140e143 In a study of 25 patients, propofol increased the QTc, but the increase was too small to be clinically significant. 144 Regardless, the combination of propofol and intubation must be managed carefully in patients with known LQTS. Although no safety issues have emerged with etomidate in patients with LQTS, etomidate increases the QT more than propofol. 145 Although thiopental also prolongs the QT interval, it favourably reduces electrical dispersion across the myocardium. 146, 147 Accordingly, it has been used without problems in patients with congenital LQTS. 130 
Volatile anaesthetics
All halogenated volatile anaesthetics prolong the QTc, an effect independent of the autonomic nervous system. 
Neuromuscular blockers and reversal agents
Succinylcholine, a commonly used depolarising neuromuscular blocker, should be avoided because it can either prolong the QT interval or lead to high vagal tone, possibly resulting in asystole. 158,161e164 Non-depolarising neuromuscular blockers (rocuronium, vecuronium, and cisatracurium) do not prolong the QTc and can be administered safely. 112, 115, 122, 135, 165 Pancuronium, however, should be avoided because of its vagolytic properties; one case of ventricular fibrillation has been reported. 112, 118 Prolongation of the QT interval has been reported with anticholinergic medications, such as glycopyrrolate and atropine; atropine-triggered TdP has been documented. 146, 166 In addition, anticholinesteraseeanticholinergic medication combinations to antagonise neuromuscular block should be administered with caution to avoid sudden and profound bradycardia, which may result in QT prolongation. 167 
Spinal and epidural anaesthesia
Spinal anaesthesia to the level of T10 may markedly prolong the QTc through the corrective increase in sympathetic tone in unblocked cardiac sympathetic fibres (T1eT4). 168 In a study of 50 healthy patients, the prolonged QT returned to normal 15 min after induction of spinal anaesthesia. 169 However, a more recent study of healthy obstetric patients undergoing Caesarean delivery showed no increases in the QTc or the T peak to T end interval after spinal anaesthesia 170 ; rather, these variables increased significantly with administration of oxytocin (5 IU). Thus, the risks and benefits must be evaluated before administering oxytocin in patients with known LQTS. Similarly, carbetocin, a synthetic analogue of human oxytocin, has also been shown in a small study to increase the QTc duration (by 18e30 ms) and, thus, should be used with caution. 171 Various case reports have established the safe use of a combined spinaleepidural anaesthetic in the obstetric management of patients with known LQTS. 119, 172 The combination of spinal and epidural anaesthetics reduces the haemodynamic response to labour or a Caesarean delivery. Because an epidural causes a more gradual change in haemodynamics, it is preferred over spinal anaesthesia in this patient group. 139 The local anaesthetics commonly used for neuraxial anaesthesia (bupivacaine and ropivacaine) do not markedly prolong QTc or electrical dispersion across the myocardium. 173, 174 However, epinephrine should not be added to a neuraxial anaesthetic because it may cause sympathetic stimulation and trigger TdP.
112,122,139
Intraoperative TdP
TdP may occur at any time, but episodes frequently are nonsustained. For patients with sustained episodes or clinically significant haemodynamic compromise, emergent asynchronous defibrillation should be performed. Any causative medications should be identified and discontinued immediately. Treatment with magnesium sulphate can effectively terminate and prevent TdP, even in the setting of normal magnesium concentrations (initial bolus of 30 mg kg À1 , followed by infusion of 2e4 mg kg
À1
).
112,175
For episodes of TdP that are associated with bradycardia, overdriving pacing should be delivered via a temporary pacemaker or the patient's own pacemaker or ICD. Typically, the pacing rate is set at 90 beats min À1 , but faster pacing rates (up to 110 beats min À1 ) may be required. For patients with acquired QT prolongation or TdP, isoproterenol or dobutamine may be used to prevent bradycardia, but in patients with congenital LQTS, such medications may worsen QT prolongation and increase risk of arrhythmias. 176 For patients with recurrent TdP, the potassium concentrations should be supplemented to the higher end of the normal range, which will help shorten the QT interval.
80, 177 Deepening of sedation may also decrease sympathetic drive and thereby decrease further ventricular arrhythmias.
116
Postoperative care and anti-emetics
All first-generation 5-HT 3 receptor antagonists can increase the QTc. From 2001 through 2008, droperidol was taken off the market because of its effect on the QTc. 178 After much debate, droperidol was again made available; currently, it is considered effective and safe in the treatment of perioperative nausea and vomiting when used at low doses, between 0.625 and 1.25 mg i.v. 179, 180 In fact, droperidol can even be used in patients with LQTS, provided they are monitored carefully. Similarly, ondansetron 4 mg can also prolong the QTc to a similar degree as droperidol 0.75 mg. Although anti-emetics potentially can trigger cardiac events in patients with LQTS, it is unacceptable to ignore their perioperative nausea and vomiting. The latest recommendation from the US Food and Drug Administration states that the QT prolongation associated with ondansetron is dose dependent and that no single i.v. dose of ondansetron should exceed 16 mg because of the risk of QT prolongation. 181 Metoclopramide (a dopamine-2 receptor antagonist) and dexamethasone can be safely administered as part of an anti-emetic regimen in patients with LQTS. 134 Other goals of postoperative care include adequate pain control and a quiet environment. The QT interval should be monitored until recovery or tachyarrhythmia therapies are restored for patients with ICDs. Any pacemaker or ICD should have the original programming settings restored, and the device should be interrogated to verify that the device function is similar to that before the procedure.
Conclusions
Most patients with either congenital LQTS or acquired QT prolongation have an unremarkable perioperative course with anaesthesia and procedures. However, the risk of arrhythmias, particularly TdP, is not inconsequential. Although no definitive guidelines exist for these patients, the recommendations described here should help clinicians avoid complications and treat arrhythmic issues for patients with genetic and non-genetic perturbations in their repolarisation reserve. 
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